OCUL - A quarter of big progress should start to garner interest

OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would seem that the expectations at this point far underestimate the likely potential long-term adoption of DEXTENZA with expanded label and reimbursement codes in place. There is no doubt that DEXTENZA represents a step function improvement in an archaic and highly complex manual eye-drop regime, it should only be a matter of execution on the company's part to fully penetrate what should be a very sizable opportunity ($500 Million - $1 Billion plus) in post surgical inflammation and pain. As the market warms up to this reality, current valuation should expand significantly.